1,249
Views
3
CrossRef citations to date
0
Altmetric
Editorial

How an engineered therapy could replace the need for potentially harmful plasma infusions

Pages 289-291 | Received 11 Jan 2018, Accepted 25 Feb 2019, Published online: 04 Mar 2019

References

  • Furlan M, Robles R, Solenthaler M, et al. Deficient activity of von willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood. 1997;89:3097–3103.
  • Tsai HM, Lian EC. Antibodies to von willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339:1585–1594.
  • Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413:488–494.
  • Scully M, Hunt BJ, Benjamin S, et al. British committee for standards in H. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158:323–335.
  • Fujimura Y, Matsumoto M, Kokame K, et al. Pregnancy-induced thrombocytopenia and TTP, and the risk of fetal death, in upshaw-schulman syndrome: a series of 15 pregnancies in 9 genotyped patients. Br J Haematol. 2009;144:742–754.
  • Moatti-Cohen M, Garrec C, Wolf M, et al. Unexpected frequency of upshaw-schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood. 2012;119:5888–5897.
  • Scully M, Gattens M, Khair K, et al. The use of intermediate purity factor VIII concentrate BPL 8Y as prophylaxis and treatment in congenital thrombotic thrombocytopenic purpura. Br J Haematol. 2006;135:101–104.
  • Peyvandi F, Mannucci PM, Valsecchi C, et al. ADAMTS13 content in plasma-derived factor VIII/von willebrand factor concentrates. Am J Hematol. 2013;88:895–898.
  • Scully M, Knobl P, Kentouche K, et al. A recombinant human ADAMTS-13: first-in-human study evaluating pharmacokinetics, safety and tolerability in cTTP patients. Blood. 2017 Nov 9;130(19):2055–2063.
  • Peyvandi F, Scully M, Kremer Hovinga JA, et al. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost. 2017;15:1448–1452.
  • Scully M, Cataland SR, Peyvandi F, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380:335–346.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.